Positions

Assistant Professor

Medicine - Hematology & Oncology
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas United States
GI medical Oncology

Addresses

O'Quinn Medical Tower at Baylor St. Luke's Medical Center's McNair Campus (Office)

Dan L Duncan Comprehensive Cancer Center
1919 Old Spanish Trail
Houston, TX 77054
United States
Phone: (832) 957-6500
Fax: (713) 610-4596
Tannaz.Armaghany@bcm.edu

Education

MD from Tabriz University

11/1996 - Tabriz, Iran

Residency at Cook County Hospital

08/2005 - chicago, Illinois United States

Fellowship at Louisiana State University Health

07/2010 - Shreveport, Louisiana United States

Hematology and Medical Oncology

Fellowship at Arizona State University

08/2011 - Tucson, Arizona United States

Integrative Medicine

Certifications

Medical Oncology Board certification

ABIM

Hematology Board certification

ABIM

Internal Medicine Board certification

ABIM

Professional Interests

• Gastrointestinal Medical Oncology
• Neuroendocrine Tumors
• Hepatocellular Carcinoma and hepatobillary cancers

Projects

OPTIM trial

Baylor College of Medicine- Dan Duncan Comprehensive cancer center

A WINDOW OF OPPORTUNITY TRIAL WITH MECLIZINE IN HEPATOCELLULAR CARCINOMA Primary Investigator

(GLYCAR STUDY) GPC3-CAR T cells for patients with hepatocellular carcinoma

Baylor College of Medicine- Dan Duncan Comprehensive cancer center

Primary Investigator

TACTOPS

Baylor College of Medicine- Dan Duncan Comprehensive cancer center

Tumor-Associated Antigen (TAA)-Specific Cytotoxic T Lymphocytes Administered in Patients With Pancreatic Chancer. Co-investigator

S1815: A PHASE III RANDOMIZED TRIAL OF GEMCITABINE, CISPLATIN, AND NAB-PACLITAXEL VERSUS GEMCITABINE AND CISPLATIN IN NEWLY DIAGNOSED, ADVANCED BILIARY TRACT CANCERS

Baylor College of Medicine- Dan Duncan Comprehensive cancer center

Co-PI

GABLE: A PILOT STUDY IN GASTRIC CANCER OF ASSIGNMENT TO POSTOPERATIVE CHEMORADIATION OR CHEMOTHERAPY BASED UPON SURGICAL LYMPH NODE ASSESSMENT AFTER PREOPERATIVE CHEMOTHERAPY, WITH GENE ASSAY AS CORRELATE OF BIOLOGIC RESPONSE

Primary Investigator

QED: A PHASE 3 MULTICENTER, OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY OF ORAL INFIGRATINIB VERSUS GEM)CITABINE WITH CISPLATIN IN SUBJECTS WITH ADVANCED/METASTATIC OR INOPERABLE CHOLANGIOCARCINOMA WITH FGFR2 GENE FUSIONS/TRANSLOCATIONS: THE PROOF TRIAL

Co-PI

Memberships

American College of Clinical Oncology

(07/2007)

Amerian Society of hematology

(07/2007)

North American Neuroendocrine Tumor Society

SWOG member

(07/2010)

Harris county Medical Society

(08/2013)

Iranian American Medical Association

President IAMA-Texas branch

Dan L Duncan Comprehensive Cancer Center

Member

International Society of Liver cancer

Associate Member

Texas Medical Association